Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab and Panobinostat in Metastatic Melanoma and NSCLC
NCT03982134Phase 1Withdrawn
- Start
- Sep 2019
- Primary completion
- May 2021
01
Overview
Phase 1, open-label, single-arm trial of spartalizumab in melanoma and non-small cell lung cancer (NSCLC). Primary endpoint: Recommended Phase II Dose at 2 years. Planned start Sep 2019; status: withdrawn.
02
Drugs
spartalizumab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03982134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982134.